Tyson Lee

Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

Robert Provenzano, Anatole Besarab, Chao Sun et al. · Clinical Journal of the American Society of Nephrology · 2016 · 293 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients

Anatole Besarab, Robert Provenzano, Joachim Hertel et al. · Nephrology Dialysis Transplantation · 2015 · 279 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Phase 1 Study of Anti-CTGF Monoclonal Antibody in Patients with Diabetes and Microalbuminuria

Sharon G. Adler, Sherwyn Schwartz, Mark E. Williams et al. · Clinical Journal of the American Society of Nephrology · 2010 · 200 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +15

Open‐label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non‐myeloid malignancies

John A. Glaspy, Nashat Gabrail, Patricia A. Locantore-Ford et al. · American Journal of Hematology · 2023 · 18 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trial

Moshe Mittelman, David H. Henry, John A. Glaspy et al. · American Journal of Hematology · 2024 · 17 citations · Full text

Medicine, Hematology, Pharmacotherapy +17